

# Florencia Cidre-Aranaz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2512781/publications.pdf>

Version: 2024-02-01

22  
papers

1,235  
citations

687220

13  
h-index

713332

21  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1930  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ewing sarcoma. Nature Reviews Disease Primers, 2018, 4, 5.	18.1	500
2	Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nature Genetics, 2015, 47, 1073-1078.	9.4	157
3	Sarcoma treatment in the era of molecular medicine. EMBO Molecular Medicine, 2020, 12, e11131.	3.3	154
4	The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget, 2016, 7, 8613-8624.	0.8	55
5	Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes. Nature Communications, 2019, 10, 4128.	5.8	51
6	EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma. Frontiers in Oncology, 2015, 5, 162.	1.3	46
7	Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma. Nature Communications, 2020, 11, 2423.	5.8	35
8	A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas. Cancer Immunology, Immunotherapy, 2020, 69, 1353-1362.	2.0	34
9	Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies. Cancer and Metastasis Reviews, 2019, 38, 625-642.	2.7	31
10	Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma. Molecular Cancer, 2022, 21, 1.	7.9	25
11	Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. Molecular Cancer, 2021, 20, 97.	7.9	24
12	Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients. EBioMedicine, 2019, 47, 156-162.	2.7	23
13	Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma. Cell Death and Disease, 2019, 10, 116.	2.7	23
14	High Specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG Positive Ewing Sarcoma. Cancers, 2020, 12, 644.	1.7	16
15	Integrative clinical transcriptome analysis reveals <i>TMPRSS2</i> dependence of prognostic biomarkers in prostate adenocarcinoma. International Journal of Cancer, 2020, 146, 2036-2046.	2.3	13
16	Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer. Nature Communications, 2021, 12, 5356.	5.8	11
17	Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma. International Journal of Cancer, 2019, 144, 859-867.	2.3	10
18	Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1. Cell Reports, 2022, 39, 110971.	2.9	6

#	ARTICLE	IF	CITATIONS
19	Tumor Growth Analysis of Ewing Sarcoma Cell Lines Using Subcutaneous Xenografts in Mice. <i>Methods in Molecular Biology</i> , 2021, 2226, 191-199.	0.4	4
20	Drug Screening by Resazurin Colorimetry in Ewing Sarcoma. <i>Methods in Molecular Biology</i> , 2021, 2226, 159-166.	0.4	3
21	Ewing Sarcoma-Specific (Re)expression Models. <i>Methods in Molecular Biology</i> , 2021, 2226, 119-138.	0.4	2
22	Analysis of Migration and Invasion in Ewing Sarcoma. <i>Methods in Molecular Biology</i> , 2021, 2226, 167-179.	0.4	1